HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pending US Dietary Guidelines Will Consider Full Life Span, Evaluate Benefits From Supplements

Executive Summary

Dietary Guidelines Advisory Committee notes additional guidelines for young children and pregnant women were required by language in the 2014 farm bill. “As a result, this edition will cover the full lifespan.”

You may also be interested in...



Study From NHIS Data Deems Multivitamin Health Benefits As Wishful Thinking; CRN Disagrees

Study by Harvard Medical researchers comparing self-reported and clinically measurable health outcomes among 4,933 MVM users and 16,670 other consumers found users self-reported 30% better overall health. CRN says the study provides only a “snapshot in time” of usage and doesn’t shed light on causality.

House Members Suggest Buying Some Supplements With Pre-Tax Savings

Eight GOP House members urge IRS to allow supplements labeled with approved health claims to be considered “medical expenses” eligible for payment with pre-tax health savings accounts beginning with tax year 2020.

Dietary Guidelines Should Endorse Regular Vitamin Use – CRN

“Using a multivitamin-mineral to fill [nutrient] gaps is a prudent way to make sure that Americans meet their targeted nutrient intakes,” says CRN science chief Duffy MacKay. The Dietary Guidelines Advisory Committee meets Sept. 16-17 for the final time before submitting its report to HHS and USDA.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel